NCNA NuCana plc
Price Chart
Executive Summary
NuCana plc announced the appointment of Ian Webster as permanent Chief Financial Officer, effective June 1, 2026. Webster had served as Interim CFO since June 2025 and as Director of Finance since 2019. The filing is a routine management change with no material financial data, though the press release notes a cash runway anticipated into 2029 and upcoming Phase 2 data readouts for NUC-7738.
Actionable Insight
This CFO appointment is routine and unlikely to move the stock. Monitor upcoming Phase 2 data readouts for NUC-7738 in 2026 as the next catalyst. The cash runway into 2029 reduces near-term dilution risk but is not a new disclosure.
Key Facts
- Ian Webster appointed permanent CFO, effective June 1, 2026; previously Interim CFO since June 2025 and Director of Finance since 2019.
- Webster has over 20 years of finance experience, including roles at Kyowa Kirin International plc and PricewaterhouseCoopers LLP.
- Company reiterates plans to generate data in 2026 from Phase 2 NuTide:701 study of NUC-7738 in combination with Keytruda for PD-1 inhibitor-resistant metastatic melanoma.
- Cash runway anticipated to extend into 2029 per forward-looking statement in the press release.
Financial Impact
No financial figures reported; cash runway guidance is forward-looking and not quantified in the filing.
Risk Factors
- Clinical-stage biotech with no approved products; pipeline failure risk remains high.
- Forward-looking cash runway depends on no material changes in operating plan or unexpected expenses.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-249817 |
| Document: d247626d6k.htm | 0001193125-26-249817 |
| Document: 0001193125-26-249817-index-headers.html | 0001193125-26-249817 |
| Document: 0001193125-26-249817-index.html | 0001193125-26-249817 |
| Document: 0001193125-26-249817.txt | 0001193125-26-249817 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
6-K
| $1.97 awaiting T+5 | awaiting T+5 | — | $1.95 (−1.02%) |
|
Jun 1, 2026
11d ago
|
6-K
| $2.17 $1.95 | ▼ −10.14% | ▼ −7.39% | $1.95 (−10.14%) |
|
May 14, 2026
29d ago
|
6-K
| $2.18 $2.02 | ▼ −7.34% | ▼ −8.30% | $1.95 (−10.55%) |
|
May 6, 2026
5w ago
|
6-K
| $2.09 $1.87 | ▲ +10.53% | ▲ +12.03% | $1.95 (+6.70%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $1.65 $1.40 | ▼ −15.15% | ▼ −13.00% | $1.95 (+18.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access